The evolution of antibiotic therapy for bacterial conjunctivitis and keratitis: 1970-2000

Cornea

Volumn 19, Issue 5, 2000, Pages 659-672

  Baum, Jules ^a   Barza, Michael ^b  

^a Boston Eye Associates   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic resistance; Antibiotic toxicity; Antibiotics; Bacterial conjunctivitis; Bacterial corneal ulcer; History; Pharmacology; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACITRACIN; CARBENICILLIN; CEFAZOLIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; FOLIC ACID ANTAGONIST; GENTAMICIN; GRAMICIDIN; IMIPENEM; LOMEFLOXACIN; NEOMYCIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFACETAMIDE; SULFONAMIDE; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CORNEA ULCER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TISSUE LEVEL; EYE IRRITATION; HISTORY; HUMAN; KERATITIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; CONJUNCTIVITIS, BACTERIAL; CORNEAL ULCER; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; HUMANS; INJECTIONS; OPHTHALMIC SOLUTIONS; PROGNOSIS;

EID: 0033813035     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003226-200009000-00011     Document Type: Review

References (227)

1. Ofloxacin monotherapy for the primary treatment of microbial keratitis: A double-masked, randomized, controlled trial with conventional dual therapy
2. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers
3. Efficacy of ofloxacin vs. cefazolin and tobramycin in the therapy for bacterial keratitis: Report from the Bacterial Keratitis Study Research Group
4. Antimicrobial-drug resistance
5. Emerging antibiotic resistance: Real and relative. Editorial
6. Gentamicin resistance in staphylococcal corneal ulcers
7. Emerging fluoroquinolone resistance in bacterial keratitis
8. Fluoroquinolones in the treatment of bacterial keratitis
9. Emerging ciprofloxacin-resistant P. aeruginosa
10. Ciprofloxacin-resistant pseudomonas keratitis
11. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin
12. Frequency of recovery of ciprofloxacin-resistant ocular isolates following topical ciprofloxacin therapy
13. Effect of ciprofloxacin concentration on mutational resistance rates in S. aureus
14. Ciprofloxacin-resistant bacterial keratitis
15. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels
16. Gentamicin-resistant pseudomonal infection. Rationale for a redefinition of ophthalmic antimicrobial sensitivities
17. Antibiotic use in ophthalmology
18. Trimethoprim-polymyxin B ophthalmic solution in the treatment of presumptive bacterial conjunctivitis: A multicenter trial of its efficacy versus neomycin-polymicin B-gramicidin and chloramphenicol ophthalmic solutions
19. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol
20. Efficacy of topical antibiotic therapy in acute conjunctivitis in children
21. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis
22. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multi-center double-blind phase III study
23. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis
24. Topical netilmicin compared with tobramycin in the treatment of external ocular infection
25. Systemic antibiotics for treatment of the conjunctivitis-otitis media syndrome
26. The changing character of corneal infectious disease
27. Corneal ulcers
28. Treatment of pseudomonas keratitis in humans
29. Recurrence of a corneal pseudomonas infection after topical steroid therapy: Report of a case
30. Management of pseudomonas keratitis
31. Pseudomonas aeruginosa keratitis: Mixed infections of the eye
32. Pseudomonas infections of the rabbit cornea treated with gentamicin
33. Genticin in conjunctivitis and keratitis
34. Antibiotic concentration in ocular tissues. Penicillin G and dihydrostreptomycin
35. The intraocular penetration of ampicillin, methicillin and oxacillin
36. Intraocular penetration of ampicillin. Animal experiment
37. Studies on the distribution of penicillin in the eye
38. Early diagnosis and therapy of bacterial corneal ulcers
39. Strategy for the initial management of suspected microbial keratitis
40. Ulcerative keratitis. Survey of 30 years' laboratory experience
41. Spectrum of microbial keratitis in South Florida
42. A review of bacterial keratitis and bacterial conjunctivitis
43. Corneal ulcers associated with contact lens wear
44. Points in the treatment of bacterial corneal ulcers
45. Current status of prevention, diagnosis and management of bacterial corneal ulcers
46. Ocular use of gentamicin and cephaloridine. II. In vitro and patient studies
47. Current concepts in ophthalmology. Ocular infections
48. Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on prevalence of organisms
49. Treatment of bacterial corneal ulcers with concentrated antibiotic eye drops
50. Outpatient treatment of microbial corneal ulcers
51. Community care of corneal ulcers
52. The importance of initial management in the treatment of severe infectious corneal ulcers
53. Bacterial keratitis
54. Bacterial keratitis
55. Bacterial and fungal keratitis
56. Corneal ulcers in two institutions in Singapore: Analysis of causative factors, organisms and antibiotic resistance
57. Intraocular penetration of cefazolin sodium in rabbits
58. Ocular penetration of subconjunctival oxacillin, methicillin and cefazolin in rabbits with staphylococcal endophthalmitis
59. Intraocular penetration of gentamicin after subconjunctival and retrobulbar injection
60. Concentration of gentamicin in experimental corneal ulcers. Topical vs. subconjunctival therapy
61. Route of antibiotic administration in bacterial keratitis
62. Treatment of pseudomonas infection in the rabbit cornea. Comparative study
63. Corneal ulcer due to Pseudomonas aeruginosa. A comparison of the disease in California and El Salvador
64. Experimental pseudomonas keratitis
65. Ocular tissue absorption of gentamicin
66. Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit
67. Ocular penetration of topically applied gentamicin
68. Topical vs. systemic gentamicin penetration into the human cornea and aqueous humor
69. Topical antibiotic therapy of staphylococcal keratitis
70. Pathogenesis and therapy of Pseudomonas aeruginosa keratitis
71. Current therapy for bacterial keratitis and bacterial conjunctivitis
72. Subtenon injection of gentamicin for bacterial infections of the eye
73. Subconjunctival gentamicin
74. Gentamicin sulfate in external eye infections
75. Comparison of the effects of continuous and intermittent systemic administration on the penetration of gentamicin into infected rabbit eyes
76. Relative efficacy of the topical use of amikacin, gentamicin and tobramycin in experimental pseudomonas keratitis
77. Tobramycin in ophthalmology
78. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses
79. The effect of tobramycin on pseudomonas keratitis
80. Cryotherapy for experimental pseudomonal keratitis
81. Nebcin in the treatment of experimental pseudomonas keratitis
82. Nebcin in the treatment of experimental pseudomonas keratitis
83. Antibiotic therapy of experimental pseudomonas keratitis in guinea pigs
84. Experimental keratitis due to Pseudomonas aeruginosa: Model for evaluation for experimental drugs
85. Therapeutic effect of topical antibiotic on untreated eye in experimental keratitis
86. Experimental pseudomonas keratitis in guinea pigs: Therapy of moderately severe infections
87. Efficacy of topical chloramphenicol and tobramycin ophthalmic solutions in preventing severe Staphylococcus aureus keratitis in rabbits
88. An evaluation of tobramycin in experimental corneal ulcers
89. The effect of tobramycin on gentamicin-resistant strains in pseudomonas keratitis
90. Proteus species isolated from human eyes
91. Pseudomonas aeruginosa keratitis treated with ticarcillin and tobramycin
92. Corneal ulcers in patients with cosmetic extended-wear contact lenses
93. Topical imipenem therapy of aminoglycoside-resistant pseudomonas keratitis in rabbits
94. Amikacin treatment of pseudomonas-caused corneal ulcer
95. Resistant pseudomonas keratitis
96. Topical fluoroquinolones: Antimicrobial activity and in vitro epithelial toxicity
97. Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for gram-positive corneal pathogens
98. Intraocular penetration of topically applied lincomycin hydrochloride in rabbits
99. Marked differences between pigmented and albino rabbits in the concentration of clindamycin in iris and choroid-retina
100. Intraocular penetration of carbenicillin in the rabbit
101. Ticarcillin in the treatment of experimental pseudomonas keratitis
102. The effect of topical ceftazidime on pseudomonas keratitis in rabbits
103. The combination of topical ceftazidime and aminoglycosides in the treatment of refractory pseudomonal keratitis
104. Norfloxacin and silver norfloxacin in the treatment of pseudomonas corneal ulcer in the rabbit
105. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: A new method for comparative evaluation of ocular drug penetration
106. Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonas keratitis
107. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental pseudomonas keratitis
108. Topical norfloxacin therapy in pseudomonas corneal ulceration
109. Topical ciprofloxacin treatment of pseudomonas keratitis in rabbits
110. Topical antibiotic therapy for the treatment of Staphylococcus aureus keratitis
111. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: Therapy with ciprofloxacin, vancomycin and cefazolin
112. Corneal stromal penetration of topical ciprofloxacin in humans
113. Corneal tissue levels of topically applied ciprofloxacin
114. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of staphylococcus and pseudomonas keratitis
115. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis
116. Absorbsion of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye
117. 0.3% Ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis
118. Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental pseudomonas keratitis
119. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis
120. Successful treatment of methicillin-resistant Staphylococcus aureus keratitis with topical ciprofloxacin
121. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis
122. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis
123. Corneal tissue levels of topically applied ofloxacin
124. Intracorneal, aqueous humor and vitreous humor penetration of topical and oral ofloxacin
125. Topical ofloxacin in the treatment of pseudomonas keratitis in the rabbit model
126. The comparative in vitro activity of ofloxacin and selected antimicrobial agents against ocular bacterial isolates
127. Pseudominas aeruginosa isolated from corneal ulcer: Susceptibility to antimicrobial agents tested alone or in combination
128. Strategies for the management of microbial keratitis
129. The inhibitory quotient: A method for interpreting minimum inhibitory concentration data
130. Quantitation of bacterial infection and antibacterial effect in the cornea
131. Staphylococcal keratitis. Experimental model in guinea pigs
132. A collagenase digestion method for bioassay of antibiotics in ocular tissues
133. Rabbit Streptococcus pneumoniae keratitis model and topical therapy
134. Comparing radioactive and trephine-disk bioassays of dicloxacillin and gentamicin in ocular tissues in vitro
135. Treatment of bacterial infections of the eye
136. Decision-making in the management of microbial keratitis
137. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears
138. Preferred routes of antibiotic administration in treatment of bacterial ulcers of the cornea
139. Bacterial corneal ulcers
140. Penetration of ocular compartments by penicillins: Analysis of factors affecting intraocular antibiotic concentration half life
141. Acute bacterial infection of the eye: Bacterial keratitis and endophthalmitis
142. Topical vs. subconjunctival treatment of bacterial corneal ulcers
143. Treatment of bacterial ulcers of the cornea in the rabbit: A comparison of administration by eye drops and subconjunctival injections
144. Corneal distribution of subconjunctival antibiotics
145. Distribution of tritiated penicillin in the rabbit eye
146. The kinetics of subconjunctival injection
147. 14 hydrocortisone. Pt. 1. Time and major route of penetration in a normal eye
148. 14C-labeled penicillin after sub-Tenon's or subconjunctival injection
149. 14C-labeled chloramphenicol following subconjunctival or sub-Tenon's injection
150. Experimental pseudomonas keratitis
151. Comparison of therapeutic routes in experimental pseudomonas keratitis
152. Topical antibiotic therapy of Pseudomonas aeruginosa keratitis
153. The effect of fortified antibiotic therapy on the visual outcome of severe bacterial corneal ulcers
154. Comparative bioavailability and efficacy of fortified topical tobramycin
155. Permeability of the cornea to topically applied drug
156. Topical tobramycin therapy of experimental pseudomonas keratitis. An evaluation of some factors that potentially enhance efficacy
157. Topically administered corticosteroids. Effect on antibiotic-treated bacterial keratitis
158. A plan for antimicrobial therapy in bacterial keratitis
159. The stability of ten antibiotics in artificial tear solutions
160. The toxicity of an eye drop and its dilution by tears
161. Optimal frequency of topical prednisone administration
162. Pharmacology of ophthalmic solutions
163. Determination of tear volume and tear flow
164. Loading doses and extended dosing intervals in topical gentamicin therapy
165. Antibiotic use in clinical ophthalmology
166. Microbial keratitis study group. The relative risk of ulcerative keratitis among users of dailywear and extended-wear soft contact lenses
167. Effect of lidocaine on the antibacterial activity of 7 antibiotics
168. Host, microbial, and pharmacological factors affecting the outcome of suppurative keratitis
169. Management of bacterial corneal ulcers
170. Antibiotic use in ophthalmology
171. Differential care of corneal ulcers in the community based on apparent severity
172. The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis
173. Community acquired corneal ulcers: The impact of cultures on management
174. The role of cultures in the management of ulcerative keratitis
175. Use of routine antibiotic sensitivity testing for the management of corneal ulcers
176. Conrad Berens Lecture. The management of infectious keratitis as we approach the 21st century
177. Pseudomonas eye infection as a cause of death in premature infants
178. Treatment of infectious scleritis and keratoscleritis
179. A rat model of bacterial keratitis. Effect of antibiotics and corticosteroid
180. Corticosteroid in experimentally induced pseudomonas keratitis
181. Combined gentamicin-tobramycin-corticosteroid treatment. II. Effect on gentamicin-resistant pseudomonas keratitis
182. Adverse external ocular effects of topical ophthalmic therapy: An epidemiologic, laboratory, and clinical study
183. Conjunctival necrosis after administration of topical fortified aminoglycosides
184. Antibiotics and corneal epithelial wound healing
185. Effect of topical antibiotic solutions on corneal epithelial wound healing
186. Corneal epithelial wound healing: A tissue culture assay on the effect of antibiotics
187. An in vitro analysis of aminoglycoside corneal epithelial toxicity
188. In vitro toxicity of gentamicin to corneal epithelial cells
189. The effect of concentrated antibiotics on the rabbit corneal epithelium
190. Ofloxacin in serum, urine and tear film after topical application
191. Deposition of ciprofloxacin to prevent reepithelialization of a corneal defect
192. Tandem scanning confocal microscopic analysis of ciprofloxacin corneal deposits in vivo
193. The effect of vancomycin on the corneal endothelium
194. Antimicrobial efficacy and corneal endothelial toxicity of DexSol corneal storage medium supplemented with vancomycin
195. Endothelial toxicity of ceftazidime in anterior chamber irrigation solution
196. Cytotoxicity of gentamicin on corneal endothelium stored in vitro
197. Antimicrobials and the corneal endothelium
198. The effect of gentamicin on the corneal endothelium. An experimental study
199. Further evaluation of a method used for investigation of toxic drug effects. Effect of gentamicin on rabbit corneal endothelium
200. Corneal endothelial changes caused by ophthalmic drugs
201. Comparison of antibiotic therapy in presumptive bacterial conjunctivitis
202. Trimethoprim-polymyxin eye drops versus neomycin-polymyxin-gramicidin eye drops in the treatment of presumptive bacterial conjunctivitis: A double-blind study
203. Clinical evaluation of trimethoprim-containing ophthalmic solutions in humans
204. Comparison of three anti-microbials for acute bacterial conjunctivitis
205. Trimethoprim-polymyxin B sulphate ophthalmic ointment in the treatment of bacterial conjunctivitis: A review of four clinical studies
206. Ofloxacin vs. tobramycin for the treatment of external ocular infection
207. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children
208. Bacterial conjunctivitis
209. Bacterial conjunctivitis
210. Bacterial infections of the conjunctiva and cornea
211. Bacterial conjunctivitis
212. Penetration of penicillin in to the eye. Further studies
213. Effects of drug vehicle on ocular uptake of tetracycline
214. Chloramphenicol penetration on, and into, the rabbit eye
215. Corneal pharmacokinetics of topical clarithromycin
216. Intraocular penetration of semisynthetic penicillins
217. Intraocular levels of cefamandole compared with cefazolin after subconjunctival injection in rabbits
218. The difficulty in determining the route of intraocular penetration of gentamicin after subconjunctival injection in the rabbit
219. Gentamicin penetration in the aqueous humor of eyes with corneal ulcers
220. Pharmacokinetics of aztreonam in rabbit eyes
221. Aureomycin, chloramphenicol and terramycin in ophthalmology
222. Ampicillin penetration in to the rabbit eye
223. Intraocular penetration of amoxicillin
224. Penetration of chloramphenicol USP (chloromycetin) into the eye
225. Ophthalmic use of clindamycin palmitate